Omeros Corporation
OMERHealthcare|Biotechnology|US
$16.92
-0.15 (-0.88%)
Cash / Share
$1.83
Clinical Trials (29)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06298955 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | P2 | Active | 25 | Open-label | OMS906 study drug |
| NCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | P2 | Recruiting | 18 | Open-label | Biological: narsoplimab |
| NCT03864133 No Drop Post-Op Cataract Surgery | Cataract | P4 | Completed | 94 | Open-label | Omidria |
| NCT04829799 Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain | Pain Reduction | P4 | Withdrawn | — | RCT, Double-blind | 1% preservative-free lidocaine, Phenylephrine 1.0%/ Ketorolac 0.3% |
| NCT01454063 Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification | Intraocular Lens Replacement | P3 | Completed | 405 | RCT, Double-blind | OMS302, Placebo |
| NCT00624845 Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy | Postoperative Pain | P2P3 | Completed | 200 | RCT, Double-blind | OMS103HP, Vehicle |
| NCT02132312 A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement | Unilateral Cataract Extraction, Congenital Cataract | P3 | Completed | 78 | RCT, Double-blind | OMS302, Phenylephrine HCl |
| NCT02093689 Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery | Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome | P3 | Terminated | 18 | Double-blind | Part 1 OMS302, Part 2 OMS302, Part 2 Placebo |
| NCT00245271 Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction | Anterior Cruciate Ligament Reconstruction | P3 | Completed | 480 | RCT, Double-blind | OMS103HP, Vehicle |
| NCT01579565 Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification | Intraocular Lens Replacement | P3 | Completed | 416 | RCT, Double-blind | OMS302, Placebo |
| NCT00226772 Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction | Knee Injuries | P3 | Completed | 326 | RCT, Double-blind | OMS103HP, Vehicle |
| NCT01406561 Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy | Meniscal Tear | P3 | Completed | 344 | RCT, Double-blind | OMS103HP-S, Vehicle |
| NCT03608033 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy | IgA Nephropathy | P3 | Terminated | 360 | RCT, Double-blind | OMS721 |
| NCT00226759 Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction | Knee Injuries | P3 | Completed | 321 | RCT, Double-blind | OMS103HP, Vehicle |
| NCT03205995 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome | Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | P3 | Terminated | 6 | Open-label | OMS721 (narsoplimab) |
| NCT01395784 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone | Opioid Abuse | P2 | Completed | 32 | Single-blind | pioglitazone |
| NCT05972967 Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab | Paroxysmal Nocturnal Hemoglobinuria | P2 | Completed | 12 | Open-label | OMS906 |
| NCT00857090 Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones | Urinary Calculi, Urinary Stones | P1P2 | Completed | 18 | RCT, Double-blind | OMS201, Vehicle |
| NCT06209736 Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | P2 | Terminated | 3 | Open-label | OMS906 study drug |
| NCT01193127 Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) | Cataract | P2 | Completed | 223 | RCT, Double-blind | OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution |
| NCT02074410 Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Huntington's Disease | P2 | Terminated | 22 | RCT, Double-blind | OMS643762, Placebo |
| NCT01395797 Pioglitazone for Heroin and for Nicotine Dependence | Heroin Dependence, Nicotine Dependence | P1P2 | Terminated | 82 | RCT, Double-blind | PIO, Placebo |
| NCT02682407 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | IgAN, LN | P2 | Terminated | 31 | RCT, Double-blind | OMS721 (narsoplimab) |
| NCT02222545 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies | Thrombotic Microangiopathies | P2 | Completed | 58 | Open-label | OMS721 |
| NCT01952132 Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects | Schizophrenia | P2 | Completed | 40 | RCT, Double-blind | OMS643762, Placebo |
| NCT00721695 Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification. | Cataract Extraction | P1P2 | Completed | 60 | RCT, Double-blind | OMS302, OMS302-PE, Vehicle |
| NCT00599664 Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones | Urinary Calculi, Urinary Stones | P1 | Completed | 11 | RCT, Double-blind | OMS201, Vehicle |
| NCT05889299 Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | P1 | Completed | 15 | Open-label | OMS906 |
| NCT04247906 Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab | Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) | APPROVED_FOR_MARKETING | — | — | Narsoplimab |